Iovance reports $363M cash, 50+ ATCs onboard for Amtagvi; frontline melanoma data shows 65.2% ORR

IOVANCE BIOTHERAPEUTICS, INC.

Cash position of ~$363M as of 3/31/2024; 600+ employees and 50+ payers covering 200M+ lives have approved Amtagvi for at least one patient.
50 Authorized Treatment Centers onboarded by 5/28/2024; targeting ~70 by end of 2024; 100+ patients enrolled by 5/9/2024.
EU submission for Amtagvi planned in 2Q2024; UK and Canada submissions in 2H2024.
Phase 2 frontline melanoma (IOV-COM-202 Cohort 1A) results: ORR 65.2%, CR 30.4%, median PFS not reached at 21.7 months follow-up.
Registrational TILVANCE-301 Phase 3 trial for frontline melanoma randomized first patient in 2Q2023; dual primary endpoints ORR and PFS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.